ID: h-455dbebe
Hypothesis
Astrocyte-Specific DGAT1 Inhibition to Prevent Lipid Droplet-Induced Neuroinflammation
Astrocyte-Specific DGAT1 Inhibition to Prevent Lipid Droplet-Induced Neuroinflammation.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 4 oppose
🧪 Overview
Astrocyte-Specific DGAT1 Inhibition to Prevent Lipid Droplet-Induced Neuroinflammation
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["DGAT1 Acyltransferase<br/>Diacylglycerol Acyltransferase"]
B["Triglyceride Synthesis<br/>Fatty Acid Incorporation"]
C["LD Formation<br/>Cytosolic Lipid Droplet Biogenesis"]
D["ER Lipid Homeostasis<br/>Membrane Fluidity Maintenance"]
E["DGAT1 Inhibition<br/>Reduced Triglyceride and Improved Insulin"]
F["Lipid Droplet Accumulation<br/>Cellular Lipotoxicity and Stress"]
G["omega-3 PUFA Supplementation<br/>DGAT1 Activity Modulation"]
A --> B
B --> C
C --> D
D --> E
F -.->|"impairs"| D
G -.->|"modulates"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix4 supports4 contradicts
Supports
Human AD brain astrocytes show marked accumulation of PLIN2-positive lipid droplets co-localizing with NLRP3 inflammasome markers
Supports
Pharmacological DGAT1 inhibition reduces lipid droplet content in iPSC-derived astrocytes and attenuates IL-1β release
Supports
DGAT1 deficiency in mice protects against high-fat diet-induced cognitive impairment
Supports
Praserone (PRX-007) is in Phase I and specifically developed for CNS indications
EosMicrobiomics pipeline
Contradicts
DGAT1 knockout mice show no cognitive protection under normal dietary conditions—benefit only observed with high-fat diet challenge
Contradicts
Lipid droplets may buffer lipotoxic species and protect cells—accumulation could be adaptive response, not causal pathology
Skeptic critique
Contradicts
Human post-mortem studies cannot distinguish between droplets causing inflammation versus inflammation causing droplets
Skeptic critique
Contradicts
iPSC astrocytes from APP/PSEN1 mutation carriers exhibit inherent metabolic abnormalities—may respond differently than sporadic AD
Skeptic critique
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — DGAT1
No curated PDB or AlphaFold mapping for DGAT1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for DGAT1 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for DGAT1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0117
Events (7d)
0
Price History
▲3.3%💾 Resource Usage
LLM Tokens
38,938
$0.1168
Total Cost
$0.1168
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF astrocytes are treated with a selective DGAT1 inhibitor (AGK-2 at 10μM) for 48 hours, THEN lipid droplet area per astrocyte will decrease by ≥50% AND secretion of inflammatory cytokines (IL-6, TNF- | Astrocytes treated with DGAT1 inhibitor will show reduced lipid droplet accumulation and lower inflammatory cytokine secretion when stimulated with IL-1β (10ng/ | — no observation — | pending | 0.70 |
| IF astrocyte-specific DGAT1 is genetically knocked out using GFAP-Cre;DGAT1-flox mice, THEN lipid droplet burden in hippocampus will be reduced by ≥60% AND microglial activation (Iba1+ area) will be a | Astrocyte-specific DGAT1 knockout mice on high-fat diet will exhibit fewer hippocampal lipid droplets and reduced microglial activation markers. | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 70%
IF astrocytes are treated with a selective DGAT1 inhibitor (AGK-2 at 10μM) for 48 hours, THEN lipid droplet area per astrocyte will decrease by ≥50% AND secretion of inflammatory cytokines (IL-6, TNF-α) will be reduced by ≥40% compared to vehicle-treated astrocytes within 72 hours.
Predicted outcome: Astrocytes treated with DGAT1 inhibitor will show reduced lipid droplet accumulation and lower inflammatory cytokine secretion when stimulated with IL
Falsification: No significant reduction in lipid droplet area (<20% change) OR no reduction in inflammatory cytokine secretion despite DGAT1 inhibition will falsify the hypothesis.
pendingconf 65%
IF astrocyte-specific DGAT1 is genetically knocked out using GFAP-Cre;DGAT1-flox mice, THEN lipid droplet burden in hippocampus will be reduced by ≥60% AND microglial activation (Iba1+ area) will be attenuated by ≥40% compared to DGAT1-flox littermate controls after 3 months of high-fat diet exposur
Predicted outcome: Astrocyte-specific DGAT1 knockout mice on high-fat diet will exhibit fewer hippocampal lipid droplets and reduced microglial activation markers.
Falsification: No reduction in hippocampal lipid droplet area (<30% change) OR no attenuation of microglial activation markers despite astrocyte-specific DGAT1 knockout will falsify the hypothesis.
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.